Acorda Therapeutics Statistics
Total Valuation
ACORQ has a market cap or net worth of $229,770. The enterprise value is $160.58 million.
| Market Cap | 229,770 |
| Enterprise Value | 160.58M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
ACORQ has 1.24 million shares outstanding. The number of shares has increased by 22.85% in one year.
| Shares Outstanding | 1.24M |
| Shares Change (YoY) | +22.85% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.33
| Current Ratio | 0.33 |
| Quick Ratio | 0.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.39 |
Financial Efficiency
Return on equity (ROE) is -2,206.90% and return on invested capital (ROIC) is -833.57%.
| Return on Equity (ROE) | -2,206.90% |
| Return on Assets (ROA) | -83.30% |
| Return on Capital (ROIC) | -833.57% |
| Revenue Per Employee | $1.15M |
| Profits Per Employee | -$2.48M |
| Employee Count | 102 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.06 |
Taxes
| Income Tax | -43.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.51% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -98.51% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 9.10 |
| Relative Strength Index (RSI) | 28.59 |
| Average Volume (20 Days) | 18,173 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ACORQ had revenue of $117.63 million and -$252.85 million in losses. Loss per share was -$203.57.
| Revenue | 117.63M |
| Gross Profit | 102.35M |
| Operating Income | -274.59M |
| Pretax Income | -296.02M |
| Net Income | -252.85M |
| EBITDA | -232.89M |
| EBIT | -264.49M |
| Loss Per Share | -$203.57 |
Balance Sheet
The company has $30.62 million in cash and $190.90 million in debt, giving a net cash position of -$160.28 million or -$129.05 per share.
| Cash & Cash Equivalents | 30.62M |
| Total Debt | 190.90M |
| Net Cash | -160.28M |
| Net Cash Per Share | -$129.05 |
| Equity (Book Value) | -157.96M |
| Book Value Per Share | -127.18 |
| Working Capital | -152.98M |
Cash Flow
In the last 12 months, operating cash flow was -$13.98 million and capital expenditures -$264,000, giving a free cash flow of -$14.25 million.
| Operating Cash Flow | -13.98M |
| Capital Expenditures | -264,000 |
| Free Cash Flow | -14.25M |
| FCF Per Share | -$11.47 |
Margins
Gross margin is 87.01%, with operating and profit margins of -233.43% and -214.95%.
| Gross Margin | 87.01% |
| Operating Margin | -233.43% |
| Pretax Margin | -251.65% |
| Profit Margin | -214.95% |
| EBITDA Margin | -197.98% |
| EBIT Margin | -224.84% |
| FCF Margin | -12.11% |
Dividends & Yields
ACORQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.85% |
| Shareholder Yield | -22.85% |
| Earnings Yield | -84,827.56% |
| FCF Yield | -4,779.92% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACORQ has an Altman Z-Score of -23.99 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.99 |
| Piotroski F-Score | 4 |